In response to criticism that the FDA harbors a gender bias agency officials have scheduled a twoday workshop in October to discuss female sexual dysfunction and ideas for developing appropriate drugs The move which was announced this week on the FDA web site comes amid ongoing controversy over claims by some consumer advocacy groups and drug makers that the agency has failed to approve medications to combat female sexual problems At the same time they argue that nearly two dozen such treatments exist for men